title: Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.
abstract: Opioids are well known for their robust analgesic effects. Chronic activation of mu opioid receptors (MOPs) is, however, accompanied by various unwanted effects such as analgesic tolerance. Among other mechanisms, interactions between MOPs and delta opioid receptors (DOPs) are thought to play an important role in morphine-induced behavioral adaptations. Interestingly, certain conditions such as inflammation enhance the function of the DOP through a MOP-dependent mechanism. Here, we investigated the role of DOPs during the development of morphine tolerance in an animal model of chronic inflammatory pain. Using behavioral approaches, we first established that repeated systemic morphine treatment induced morphine analgesic tolerance in rats coping with chronic inflammatory pain. We then observed that blockade of DOPs with subcutaneous naltrindole (NTI), a selective DOP antagonist, significantly attenuated the development of morphine tolerance in a dose-dependent manner. We confirmed that this effect was DOP mediated by showing that an acute injection of NTI had no effect on morphine-induced analgesia in naive animals. Previous pharmacological characterizations revealed the existence of DOP subtype 1 and DOP subtype 2. As opposed to NTI, 7-benzylidenenaltrexone and naltriben were reported to be selective DOP subtype 1 and DOP subtype 2 antagonists, respectively. Interestingly, naltriben but not 7-benzylidenenaltrexone was able to attenuate the development of morphine analgesic tolerance in inflamed rats. Altogether, our results suggest that targeting of DOP subtype 2 with antagonists provides a valuable strategy to attenuate the analgesic tolerance that develops after repeated morphine administration in the setting of chronic inflammatory pain.
authors: Department of Anesthesiology, College of Physicians and Surgeons, Columbia University Medical Center, Columbia University, P&S Box 46, 630 West 168th Street, New York, NY, 10032, USA; Department of Physiology and Biophysics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, QC, J1H 5N4, Canada.
authors: H
authors: H
authors: Beaudry
authors: L
authors: L
authors: Gendron
authors: J A
authors: JA
authors: Morón
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D001597:Benzylidene Compounds / Q000494:pharmacology; D059350:Chronic Pain / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance / Q000502:physiology*; D005620:Freund's Adjuvant; D006614:Hindlimb; D007249:Inflammation / Q000503:physiopathology*; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D017207:Rats, Sprague-Dawley; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D000701:Analgesics, Opioid; D001597:Benzylidene Compounds; D009292:Narcotic Antagonists; D017465:Receptors, Opioid, delta; C068868:naltrindole benzofuran; C077358:7-benzylidenenaltrexone; D009271:Naltrexone; D009020:Morphine; D005620:Freund's Adjuvant; C055382:naltrindole
keywords: antagonist; heteromer; hyperalgesia; inflammation; opioid
references: J Pharmacol Exp Ther. 1992 Oct;263(1):147-52
references: 1328602
references: J Pharmacol Exp Ther. 1991 Jul 1;258(1):299-303
references: 1649297
references: Peptides. 1993 Sep-Oct;14(5):893-907
references: 8284266
references: Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10540-4
references: 7479836
references: Eur J Pharmacol. 1995 Nov 3;286(1):105-8
references: 8566146
references: Brain Res Bull. 1996;39(3):185-8
references: 8866695
references: Brain Res. 1997 Jan 9;744(2):327-34
references: 9027392
references: J Pharmacol Exp Ther. 1997 Jun;281(3):1350-6
references: 9190871
references: Am J Physiol. 1998 Mar;274(3 Pt 2):H909-14
references: 9530203
references: J Neurosci. 2005 Mar 23;25(12):3229-33
references: 15788780
references: Eur J Pharmacol. 1991 Mar 5;194(2-3):135-43
references: 1676373
references: Br J Pharmacol. 2015 Jan;172(2):403-19
references: 24665909
references: J Pharmacol Exp Ther. 1991 Aug;258(2):583-7
references: 1650835
references: Eur J Pharmacol. 1992 Jul 21;218(1):195-6
references: 1327826
references: Mol Pharmacol. 2005 Oct;68(4):1079-86
references: 16006595
references: Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19208-13
references: 16365317
references: J Neurosci. 2006 Jan 18;26(3):953-62
references: 16421315
references: Trends Pharmacol Sci. 2006 Jun;27(6):324-9
references: 16678916
references: Neuroscience. 2007 Jan 5;144(1):263-74
references: 17055663
references: Eur J Pharmacol. 2007 Apr 10;560(2-3):132-41
references: 17307158
references: Eur J Pharmacol. 2007 Jul 2;566(1-3):75-82
references: 17383633
references: Br J Pharmacol. 2007 Jul;151(6):877-87
references: 17502848
references: Neuroscience. 2007 Dec 19;150(4):807-17
references: 17997230
references: Eur J Neurosci. 2008 May;27(10):2558-67
references: 18513322
references: Biol Psychiatry. 2009 Jan 15;65(2):169-74
references: 18950747
references: Neuropsychopharmacology. 2009 Mar;34(4):887-98
references: 18704097
references: Neuroscience. 2009 Jun 30;161(2):381-91
references: 19328839
references: J Neurosci. 2000 Feb 1;20(3):1249-59
references: 10648729
references: Neuron. 1999 Sep;24(1):243-52
references: 10677041
references: J Neurosci. 2001 Oct 1;21(19):7598-607
references: 11567050
references: J Pharmacol Exp Ther. 2002 Nov;303(2):723-9
references: 12388657
references: J Neurosci. 2002 Dec 15;22(24):10906-13
references: 12486185
references: Pain. 2003 Jan;101(1-2):199-208
references: 12507715
references: Eur J Pharmacol. 2003 Apr 25;467(1-3):233-4
references: 12706480
references: J Neurosci. 2003 Jun 15;23(12):4888-98
references: 12832511
references: Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5135-9
references: 15044695
references: Pain. 2004 Jun;109(3):266-73
references: 15157687
references: J Med Chem. 2004 Jun 3;47(12):2969-72
references: 15163177
references: J Neurosci. 2004 Jun 16;24(24):5549-59
references: 15201327
references: Eur J Pharmacol. 1988 Jan 27;146(1):185-6
references: 2832195
references: J Pharmacol Exp Ther. 1991 May;257(2):676-80
references: 1851833
references: J Pharmacol Exp Ther. 1991 Jun;257(3):1069-75
references: 1646319
references: Neuropsychopharmacology. 2010 Mar;35(4):955-66
references: 19956087
references: Sci Signal. 2010;3(131):ra54
references: 20647592
references: Eur J Neurosci. 2010 Aug;32(4):625-31
references: 20626460
references: Bull Exp Biol Med. 2010 Oct;149(5):591-3
references: 21165394
references: Neuron. 2011 Jan 13;69(1):120-31
references: 21220103
references: Biol Psychiatry. 2011 Apr 1;69(7):700-3
references: 21168121
references: J Surg Res. 2011 Aug;169(2):267-76
references: 20444473
references: Expert Rev Mol Med. 2012;14:e9
references: 22490239
references: Acad Emerg Med. 2014 Jan;21(1):31-9
references: 24552522
references: J Pharmacol Exp Ther. 1993 Mar;264(3):1141-5
references: 8383738